Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Ken Kato*, Byoung Chul Cho, Masanobu Takahashi, Morihito Okada, Chen Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung Ju Ahn, Yasuo Hamamoto, Yuichiro Doki, Chueh Chuan Yen, Yutaro Kubota, Sung Bae Kim, Chih Hung Hsu, Eva Holtved, Ioannis Xynos, Mamoru Kodani, Yuko Kitagawa

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Fingeraftryk Dyk ned i forskningsemnerne om 'Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial'. Sammen danner de et unikt fingeraftryk.

Medicin og biovidenskab